Paclitaxel interactions
Full monograph for PaclitaxelCheck it against another medicine
Medicines
565 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration with certain antiretroviral agents such as protease inhibitors and delavirdine may increase the plasma concentrations and pharmacologic… | 17 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration with certain antiretroviral agents such as protease inhibitors and delavirdine may increase the plasma concentrations and pharmacologic… | 17 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with certain antiretroviral agents such as protease inhibitors and delavirdine may increase the plasma concentrations and pharmacologic… | 17 sources — open the full entry |
| Rotavirus Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of… | 9 sources — open the full entry |
| Thalidomide | Major | Synergy | Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism… | 20 sources — open the full entry |
| Tofacitinib | Major | Others | Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 1 sources — open the full entry |
| Upadacitinib | Major | Others | Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. | 1 sources — open the full entry |
| Yellow Fever Vaccine | Major | Others | The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of…2 documented mechanisms | 19 sources — open the full entry |
| Abametapir | Moderate | Metabolism | Based on in vitro inhibition data, a single topical application of abametapir lotion may increase plasma concentrations of drugs that are substrates of CYP450… | 1 sources — open the full entry |
| Abiraterone Acetate | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate… | 17 sources — open the full entry |
| Alpelisib | Moderate | Excretion | Coadministration with alpelisib may theoretically increase the plasma concentrations of drugs that are substrates of organic anion transporter (OAT3)… | 5 sources — open the full entry |
| Amiodarone Hydrochloride | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate… | 17 sources — open the full entry |
| Amlodipine Besilate + Atorvastatin | Moderate | Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms | 4 sources — open the full entry |
| Apalutamide | Moderate | Metabolism | Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is… | 13 sources — open the full entry |
| Aprepitant | Moderate | Metabolism | Coadministration with aprepitant or its prodrug, fosaprepitant, may increase the plasma concentrations of chemotherapeutic agents that are primarily… | 6 sources — open the full entry |
| Asciminib | Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Atorvastatin + Ezetimibe | Moderate | Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms | 4 sources — open the full entry |
| Atorvastatin Calcium | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Azathioprine | Moderate | Synergy | The use of azathioprine with other immunosuppressive or myelosuppressive agents may result in additive hematologic toxicities and increased risk of infections… | 3 sources — open the full entry |
| Azithromycin DihydratebaseOphthalmic | Moderate | Absorption | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the blood concentrations of the taxanes, docetaxel and paclitaxel, which have been shown… | 22 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Metabolism · Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…3 documented mechanisms | 21 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Others | The potential effects of vitamin E on cancer chemotherapy and radiation have not been established. Because vitamin E is an antioxidant, pharmacologic doses… | 9 sources — open the full entry |
| Betamethasone + Clotrimazole | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate… | 17 sources — open the full entry |
| Betamethasone + Clotrimazole + Gentamicin | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate… | 17 sources — open the full entry |
| Bicalutamide | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate… | 17 sources — open the full entry |
| Bortezomib | Moderate | Synergy | Bortezomib can cause peripheral neuropathy, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk and/or… | 4 sources — open the full entry |
| Bosentan Monohydrate | Moderate | Metabolism | Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is… | 13 sources — open the full entry |
| Brigatinib | Moderate | Metabolism | Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is… | 13 sources — open the full entry |
| Cabazitaxel | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Cabozantinib | Moderate | Others | Based on in vitro inhibition data, coadministration with cabozantinib may increase the plasma concentrations of drugs that are substrates of the P-glycoprotein… | 2 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Moderate | Metabolism · Unknown | Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is…2 documented mechanisms | 13 sources — open the full entry |
| Capmatinib Hydrochloride | Moderate | Absorption | Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp)… | 1 sources — open the full entry |
| Carbamazepine | Moderate | Metabolism | Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is… | 13 sources — open the full entry |
| Carbidopa + LevodopaExtended releaseProlonged release | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carboplatin | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carfilzomib | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Carvedilol | Moderate | Absorption | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the blood concentrations of the taxanes, docetaxel and paclitaxel, which have been shown… | 22 sources — open the full entry |
| Cenobamate | Moderate | Metabolism | Theoretically, coadministration with drugs that are inducers of CYP450 2C8 and/or 3A4 may decrease the plasma concentrations of paclitaxel, which is… | 13 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Coadministration with inhibitors of CYP450 2C8 and/or 3A4 may increase the plasma concentrations of paclitaxel, which has been found in vitro to be a substrate… | 17 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Synergy · Unknown | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk…2 documented mechanisms | 4 sources — open the full entry |
| Chloroquine Phosphate | Moderate | Synergy | The risk of peripheral neuropathy may be increased during concurrent use of two or more agents that are associated with this adverse effect. Patient risk… | 4 sources — open the full entry |
Food & lifestyle
grapefruit juice
ModerateMetabolism
Coadministration with inhibitors of CYP450 3A4, such as grapefruit juice, may increase the plasma concentrations of paclitaxel, which is a substrate of the isoenzyme
What to do: Caution is recommended if paclitaxel is to be used in combination with grapefruit and grapefruit juice. Patients should be closely monitored for the development of paclitaxel toxicity, including diarrhea, mucositis, myelosuppression, and peripheral neuropathy and dose adjustment considered per local treatment protocols.
9 sources
- "Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer (2001):
- Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91
- McInnes GT, Brodie MJ "Drug interactions that matter: a critical reappraisal." Drugs 36 (1988): 83-110
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Yong WP, Wang LZ, Tham LS, et al. "A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers." Cancer Chemother Pharmacol 62 (2008): 243-51
- Cerner Multum, Inc. "Australian Product Information." O 0
- Engels FK, Mathot RA, Loos WJ, van Schaik RH, Verweij J "Influence of high-dose ketoconazole on the pharmacokinetics of docetaxel." Cancer Biol Ther 5 (2006): 833-9
- Valenzuela B, Rebollo J, Perez T, Brugarolas A, Perez-Ruixo JJ "Effect of grapefruit juice on the pharmacokinetics of docetaxel in cancer patients: a case report." Br J Clin Pharmacol (2011):
Show all 9 sourcesShow fewer sources
- Starr SP, Hammann F, Gotta V, et al. "Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity." Br J Clin Pharmacol 450 (2016): 22-27